Healthcare Nov 20, 2020 07:15 PM (GMT+8) · EqualOcean
Guizhou Sanli announced that the company intends to participate in the capital increase of Guizhou Hanfang Pharmaceutical Co., Ltd. (hereinafter referred to as "Hanfang pharmaceutical") together with Sheng Yongjian, the company's director and shareholder holding more than 5%. Among them, the company invested 111.9 million yuan to acquire 25.64% equity of Hanfang pharmaceutical; Sheng Yongjian plans to invest 50 million yuan to acquire 11.46% equity of Hanfang pharmaceutical. The overseas investment is conducive to expanding the product categories of the company and alleviating the risk of relatively concentrated products. Hanfang Pharmaceutical Co., Ltd. is currently operating at a loss and is not expected to make a significant contribution to the company's short-term performance.